MedTrace Logo

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

NCT03657446 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-11-20

No results posted yet for this study

Summary

The study will investigate whether administration of clazosentan can affect normal heart function in healthy subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

Clazosentan

Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

DRUG

Placebo

Matching placebo infusion

DRUG

Moxifloxacin

Film-coated tablet containing 400 mg moxifloxacin

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2018-10-26
Completion
2018-10-26

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657446 on ClinicalTrials.gov